While there had been some doubt if Isis (IONS 1.16%) and its partner Sanofi (SNY 0.19%) would have their inherited cholesterol disorder drug Kynamro approved, news today that it received FDA approval shot Isis shares up 10%, while competitor Aegerion (NASDAQ: AEGR) was down 2% on the news. In this video, Motley Fool health-care analyst David Williamson tells us some of the headwinds and tailwinds investors can expect for the drug, and how well he sees it competing with Aegerion's Juxtapid in the same space.